Physician profile
Mark Johns
NPI 1407040884
$3,041.47
in general payments reported to CMS, 2019-2025
29 companies · $825 in 2025
The $825 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.42 · 2022: $157 · 2023: $694 · 2024: $1,329 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.45 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $159.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,467.27 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $236.94 | 2023-2025 | Lynparza, Enhertu |
| Pfizer INC. | $156.87 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $146.97 | 2023 | Akeega, Erleada |
| Astellas Pharma US INC | $124.13 | 2024 | Xtandi |
| Merck Sharp & Dohme LLC | $123.84 | 2023 | Lynparza |
| Progenics Pharmaceuticals, INC. | $121.41 | 2024 | |
| Bioprotect Medical, INC. | $116.55 | 2024 | Bioprotect Balloon Implant System |
| Janssen Biotech, INC. | $115.93 | 2022-2025 | Erleada |
| Myriad Genetic Laboratories, INC. | $108.77 | 2023 | Prolaris |
| Foundation Medicine, INC. | $80.00 | 2022 | |
| Abbvie INC. | $53.50 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $29.55 | 2023 | Imbruvica |
| Sun Pharmaceutical Industries INC. | $22.91 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.67 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $21.55 | 2023 | Libtayo |
| Aveo Pharmaceuticals, INC. | $20.37 | 2025 | |
| Eisai INC. | $19.00 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $16.58 | 2023 | Opdivo |
| Tactile Systems Technology INC | $14.24 | 2023 | Flexitouch Plus, Entre Plus |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Epizyme, INC. | $11.50 | 2021 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Johns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.